Bilal Hameed, MD
Neuromuscular Medicine · New London, CTNPI 1063725190
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 38.9% of the total. Reporting peaked in 2019 at $637 and has fallen 90.1% since, to $63 in 2023.
Across 50 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$398
- Novartis$253
- EMD Serono, Inc.$128
- Merz North America, Inc.$53
- Biogen$47
- Acadia Pharmaceuticals Inc$35
- plus $108 from 7 others
What the payments were for
- Food & beverage$1,022100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 15 | $398 |
| Novartis | 12 | $253 |
| EMD Serono, Inc. | 5 | $128 |
| Merz North America, Inc. | 3 | $53 |
| Biogen | 3 | $47 |
| Acadia Pharmaceuticals Inc | 3 | $35 |
| Tanabe Pharma America, Inc. | 2 | $26 |
| Amgen | 2 | $25 |
| Sanofi | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
| UCB, Inc. | 1 | $11 |
| Scilex Pharmaceuticals Inc. | 1 | $11 |
How this compares
Too few neuromuscular medicine providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 31 | $451,663 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 52 | $363,090 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 14 | $302,761 |
| Emgality PenGalcanezumab-Gnlm | 18 | $16,594 |
| LyricaPregabalin | 11 | $6,692 |
| Mycophenolate Mofetil | 34 | $4,416 |
| Gabapentin | 173 | $3,750 |
| Pregabalin | 116 | $2,955 |
| Pyridostigmine Bromide | 48 | $2,349 |
| Levetiracetam | 55 | $1,804 |
| Zonisamide | 27 | $1,647 |
| Memantine Hcl | 70 | $1,471 |
| Duloxetine Hcl | 57 | $1,310 |
| Lacosamide | 16 | $1,266 |
| Donepezil Hcl | 76 | $1,018 |
Paid to pharmacies, not to this prescriber.
Other neuromuscular medicine in New London
- John TauroNorwich$54K
- Sasa ZivkovicGuilford$37K
- Bhaskar RoyNew Haven$17K
- Barry GordonMeriden$3K
- Kevin FeliceNew Britain$2K
- David TinklepaughMystic$2K
- Ylec Cardenas CastilloNew Haven$1K
- Arpad FejosMiddletown$1K
- Zara KhanWestport$1K
- Idaira Aguilar TejedorStratford$864
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.